Company Profile

OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Employees

128

Sector

Pharmaceuticals

More about the company

23/05/25	OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P Global BMI Index	CI
23/05/25	OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P TMI Index	CI
22/05/25	BioPharma Credit Receives $83 Million from OptiNose Sale	MT
21/05/25	Paratek Pharmaceuticals, Inc completed the acquisition of OptiNose, Inc. from group of shareholders.	CI
21/05/25	OptiNose, Inc. Announces Management Changes	CI
20/05/25	OptiNose, Inc.(NasdaqGM:OPTN) dropped from NASDAQ Composite Index	CI
14/05/25	OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
26/03/25	OptiNose Q4 Income From Operations USD 354 Thousand	RE
26/03/25	OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
25/03/25	OptiNose, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/03/25	HC Wainwright Downgrades OptiNose to Neutral From Buy, Cuts Price Target to $9 From $18	MT
20/03/25	Health Care Flat on Defensive Demand -- Health Care Roundup	DJ
20/03/25	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT

21/03/25	HC Wainwright Downgrades OptiNose to Neutral From Buy, Cuts Price Target to $9 From $18	MT
20/03/25	Piper Sandler Downgrades OptiNose to Neutral From Overweight, $9 Price Target	MT
20/03/25	Lake Street Downgrades OptiNose to Hold From Buy, Price Target is $9	MT
18/03/24	Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	MT
11/03/24	HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	MT

21/05/25	Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies	AQ
15/05/25	OptiNose: Q1 Earnings Snapshot	AQ
29/04/25	OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN	BU
26/03/25	OptiNose: Q4 Earnings Snapshot	AQ
26/03/25	Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights	AQ

3 years	4.81	31.5
5 years	4.81	64.5
10 years	4.81	450

Manager	Title	Age	Since
Evan Loh CEO	Chief Executive Officer	67	20/05/2025
Michael C. Berkey CTO	Chief Tech/Sci/R&D Officer	-	31/12/2019
Jonathan Neely IRC	Investor Relations Contact	-	31/07/2020

OPTINOSEPAR Share Price

Stocks

OPTN

US68404V2097

Pharmaceuticals

Latest news: OPTINOSEPAR

Analysts' recommendations: OPTINOSEPAR

Press Releases: OPTINOSEPAR

News in other languages: OPTINOSEPAR

Quotes and Performance

Price Extremes

Managers and Directors: OPTINOSEPAR

Latest insider transactions

Other Pharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/05/25	Paul Kohler	Issuer sale	Chief Financial Officer	82,491	0.8204%
21/05/25	Kyle Dempsey	Issuer sale	Director	12,624	0.1255%
21/05/25	Eric Bednarski	Issuer sale	Director	12,624	0.1255%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OPTINOSEPAR	-1.13%	-.--%	-	-	97.22M
ELI LILLY AND COMPANY	-2.54%	+1.31%	+55.10%	+120.84%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+37.07%	+74.26%	636B
ABBVIE INC.	+0.16%	+0.08%	+25.14%	+97.36%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+43.92%	+64.55%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.63%	+40.56%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.46%	+51.48%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.62%	+26.97%	266B
AMGEN INC.	-1.79%	+1.57%	+49.97%	+60.87%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.24%	+101.19%	193B
Average	-1.10%	+2.17%	+36.91%	+70.90%	444.93B
Weighted average by Cap.	-1.35%	+2.66%	+40.99%	+82.13%